Integrating evidence from multiple sources to evaluate post-approval safety: an example of sildenafil citrate and cardiovascular events

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current Medical Research and Opinion

• Publication date

  2008-05-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1185/03007990802128781PMID 18507892
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular outcomes among sildenafil users: results of the International Men’s Health Study

  2008cited by this paper
• Comparisons and Applications of Quantitative Signal Detections for Adverse Drug Reactions (ADRs): An Empirical Study Based On The Food And Drug Administration (FDA) Adverse Event Reporting System (AERS) And A Large Medical Claims Database

  2008cited by this paper
• Global Drug Surveillance: The WHO Programme for International Drug Monitoring

  2007cited by this paper
• Prevalence and risk factors for erectile dysfunction in the US.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• A prospective study of risk factors for erectile dysfunction.

  2006cited by this paper
• Past, present, and future: a 7‐year update of Viagra® (sildenafil citrate)

  2005cited by this paper
• Erectile dysfunction and subsequent cardiovascular disease.

  2005cited by this paper
• Replication of the Weber Effect Using Postmarketing Adverse Event Reports Voluntarily Submitted to the United States Food and Drug Administration

  2004cited by this paper
• Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999

  2004cited by this paper
• Adverse Event Reporting with Selective Serotonin-Reuptake Inhibitors

  2003cited by this paper
• A 4-year update on the safety of sildenafil citrate (Viagra).

  2002cited by this paper
• Responding to Signals

  2002cited by this paper
• Spontaneous Reporting in the United States

  2002cited by this paper
• Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England

  2001cited by this paper
• Initial uptake in use of sildenafil in general practice

  2001cited by this paper
• ‘Viagra® Effect’ – Influence of Mass Media on Patient Behavior

  2001cited by this paper
• IS ERECTILE DYSFUNCTION A MARKER FOR CARDIOVASCULAR DISEASE?

  2001cited by this paper
• Temporal Patterns of NSAID Spontaneous Adverse Event Reports

  2001cited by this paper
• Some men who take Viagra die--why?

  2000cited by this paper
• Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease.

  1999cited by this paper
• Sildenafil: medical advance or media event?

  1998cited by this paper
• Limitations and strengths of spontaneous reports data.

  1998cited by this paper
• Prospective Study of the Influence of the Media on Reporting Medical Events

  1990cited by this paper
• Ulcerogenicity of piroxicam: an analysis of spontaneously reported data.

  1987cited by this paper
• Ulcerogenicity of piroxicam: an analysis of spontaneously reported data.

  1987cited by this paper
• Advances in inflammation research

  1979cited by this paper

• The Origins and Proliferation of Unfounded Comparisons Regarding the Safety of Mifepristone

  2025cites this paper
• Safety of medicines and vaccines - building next generation capability.

  2021cites this paper
• The Use of Randomized Controlled Trials in Pharmacoepidemiology

  2019cites this paper
• The Role of Pharmacoepidemiology in Industry

  2019cites this paper
• Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?

  2016cites this paper
• Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database: F. Giuliano, G. Jackson, F. Montorsi, A. Martin-morales, and P. Raillard.

  2014cites this paper
• Therapeutic Advances in Drug Safety Lesley Wise Risks and benefits of ( pharmaco ) epidemiology

  2011cites this paper
• Risks and benefits of (pharmaco)epidemiology

  2011cites this paper
• Is the Large Simple Trial Design Used for Comparative, Post-Approval Safety Research?

  2011cites this paper
• Safety and Quality Assessment of 175 Illegal Sexual Enhancement Products Seized in Red-Light Districts in Singapore

  2009cites this paper
• Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database

  2009cites this paper